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ABSTRACT 
New methods enable new discoveries. My time as a PhD student has run in parallel with the 
maturation of the RNA-seq method, and I have used it to discover basic properties of gene 
expression and transcriptomes. My part has been bioinformatics – the computer analysis of 
biological data. 
RNA-seq quantifies gene expression for all genes in one experiment, allowing discoveries 
without prior knowledge, as opposed to single-gene hypothesis testing. When I started my PhD, 
this was done by microarray followed by qRT-PCR validation, which can be arduous. In contrast 
to microarrays, RNA-seq quantifies expression with little ambiguity of which gene each 
expression value corresponds to, and in absolute terms. But at the time, data analysis of RNA-seq 
was full of unknowns and there were little software available. Nowadays, partly the result of my 
work, the data analysis is much less complicated, and RNA-seq can be performed on diminutive 
samples, down to single cells, which was not viable using microarrays. 
My first study (Paper I) used one of the very first RNA-seq datasets to study general features of 
transcriptomes, such as mean mRNA length (~1,500 nt) and the number of genes expressed per 
tissue (~13,000). I also found special features of some tissues: the liver transcriptome is 
dominated by a few highly expressed gene, brain expresses especially long mRNAs and testis 
expresses many more genes than other tissues. 
Following this tissue RNA-seq study, I evaluated a new library preparation method for single-cell 
RNA-seq (Paper III), developed before the prevalence of single-cell RNA-seq. I used technical 
replicates to show that the method was accurate and reliable for the more highly expressed genes 
at single-cell RNA levels, and with input RNA amounts corresponding to >50 cells it produced as 
good quality data as bulk RNA-seq. Then the method was applied on melanoma cells isolated 
from human blood, and I listed surface antigen genes that distinguished these circulating tumour 
cells from other cells in the blood. 
This single-cell RNA-seq method was then applied on pre-implantation embryo cells (Paper IV). 
Using first-generation crosses between two mouse strains, I could separate the expression from 
the maternal and the paternal copies of the genes. I found that 12-24% of the genes express only 
one of their two copies in any given cell, in a random manner that affects almost all the expressed 
genes. I also found that the two copies are expressed independently from each other. 
Finally, I studied Sox transcription factors during neural development (Paper II), combining 
RNA-seq and microarray data for different cell types with ChIP-seq data for transcription factor 
binding and histone modifications. I found that Sox proteins bind to the enhancers active in the 
stem cells where the Sox proteins are active, but also to enhancers specific to subsequent cells in 
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development. I also found that different Sox factors bind to much the same enhancers, and that 
they can induce histone modifications. 
In conclusion, my work has advanced the RNA-seq method and increased the understanding of 
transcriptional regulation and output. 
 
 iii 
SAMMANFATTNING PÅ SVENSKA 
Nya metoder möjliggör nya upptäckter. Min tid som doktorand har gått parallellt med mognaden 
av metoden RNA-sekvensering, och jag har använt den för att upptäcka grundläggande 
egenskaper hos valet av vilka gener som används i en cell och populationen av de RNA-
molekyler som gener gör upphov till när de är aktiva.  
RNA-sekvensering mäter aktiviteten för alla gener i ett experiment, vilket möjliggör upptäckter 
utan förkunskaper, till skillnad från hypotesprövning med enskilda gener. När jag startade som 
doktorand gjordes detta genom tekniken microarray. Man fick sedan följa upp med tekniken 
qRT-PCR, eftersom microarrayer inte var tillförlitliga nog. RNA-sekvensering behöver inte detta. 
Däremot var data-analysen av RNA-sekvenseringsdata full av oklarheter och det var ont om 
metoder och datorprogram. Delvis på grund av mitt arbete är data-analysen numera betydligt 
mindre komplicerat, och dessutom kan RNA-sekvensering utföras på mycket små prover, ner till 
enstaka celler. 
Denna avhandling sammanfattar de fyra huvudprojekt jag arbetade på under min doktorandtid. I 
det första studerade jag antalet gener olika vävnader använder och om de likheter som finns 
mellan vävnader i gen-användning. Nästa arbete beskriver en metod för att använda RNA-
sekvensering på enskilda celler. Ett tredje arbete använder denna encellsmetod för att studera 
slumpmässighet i gen-aktivitet, där jag såg att gener ganska ofta bara använder bara den 
maternella eller bara den paternella kopian av genen i en cell. Det sista arbetet handlar om steget 
före en gen är uttryckt, då proteiner binder till DNA en lång bit ifrån de gener de ska påverka; här 
fann jag att en grupp sådana proteiner (Sox) binder ett bra tag i förväg innan genen ska bli aktiv 
under embryonalutvecklingen. 
Sammanfattningsvis har mitt arbete avancerat RNA-sekvenseringsmetoden och ökat förståelsen 
för valet av genaktivering inom celler. 
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INTRODUCTION 
 
Transcription 
The different cell types (muscle cells, liver cells etc) of the body share the same DNA and 
therefore the same set of genes. But the set of genes each cell type actually uses differs, both by 
its cell type and by its responses to the local environment. A gene needs to copy (transcribe) itself 
into RNA to have an effect. Apart from being transcribed into RNA or not, the number of RNA 
molecules can be important since e.g. more RNA for a particular protein can produce more of that 
protein. One measures RNA amounts to learn if and how much active different genes are, in a 
particular cell or in a larger group of cells. This can tell which genes are involved in reacting to a 
stimulus or differ in activity during a disease, as well as providing a signature for each cell type. 
Whether a gene should be transcribed or not is controlled by DNA regions called enhancers1. 
Their DNA binds proteins called transcription factors, for which over a thousand exist in human2. 
Not the same transcription factors are present in all cell types and under all external conditions, 
therefore not all enhancers are active in every cell but only a limited subset. Each gene has many 
enhancers that control it, located nearby on the DNA. When an enhancer is bound by a sufficient 
number of proteins, it can come in proximity to the start of the gene by DNA looping. There, it 
coaxes the protein RNA polymerase into moving down along the gene (RNA polymerase has a 
molecular motor function), transcribing the gene as it moves3. 
 
Methods and history of RNA quantification 
RNA amounts could be measured already in the 1970s. Northern blot, from 19774, is a method 
that can measure RNA amount by using a radioactively labeled RNA probe5. Soon there was also 
RNA-FISH6, a method which uses a fluorescently labeled oligonucleotide to make microscopy 
pictures where RNAs with a particular sequence light up as dots, or as a smear depending on 
resolution7. This method dates from 19827, and can both determine if the gene is expressed, 
where the RNA is located and sometimes even quantify how much RNA there is. Ten years later8 
came qRT-PCR, which converts RNA to cDNA and measures total DNA amount during DNA 
amplification as the intensity of a DNA-binding dye. Compared to Northern it is faster and more 
sensitive, the latter a result of including DNA amplification (i.e. PCR)9. The first quantitative 
sequencing-based method, SAGE, came in 199510. Because it used short (9 bp at the beginning in 
1995) sequences to identify genes, there were difficulties with ambiguity. The tags were produced 
by restriction enzymes that cut a set distance from their binding sites. The sequencing itself was 
 2 
done by concatenating the small DNA fragments and running Sanger sequencing10. Gene 
expression microarrays also date from 199511 and became the dominant method for quantifying 
RNA from thousands of genes in an experiment, rather than SAGE. Microarrays typically rely on 
oligonucleotide probes (DNA that is tens of bases long) to bind fluorescently labeled cDNA, with 
the oligonucleotides arranged in a pre-determined pattern so that spots will light up at known 
places when a cDNA for a particular gene is present, with light intensity proportional to the 
amount of cDNA. The ability of microarrays to measure thousands of genes at the same time 
brought discoveries that methods that only measure a few genes at a time could not have 
achieved12. 
Sequencing of fragments of RNA, called expressed sequence tags, has been around for decades, 
and was used to discover genes13 rather than for RNA quantification. The history of RNA-
sequencing starts when the DNA sequencing machines by Solexa/Illumina allowed sequencing of 
millions of RNA pieces per sample. Before these machines, sequencing of random RNA 
fragments was limited to gene discovery, because of cost and low sequence depth14. With the 
new technology, the number of sequenced fragments per gene was dramatically increased such 
that the counts would correlate with the expression level of the gene to reflect how much RNA 
from each gene there was in the sample. The first publications came out in May 200815,16. At this 
time the cost associated with RNA-seq was high, which meant that studies used few or no 
replicates (that is, preparing the same type of material twice or more and sequencing separately) 
to control for biological and technical variation. Yet the improvement in data quality, allowing 
genes to be quantified in absolute terms (e.g. one gene could be determined to be expressed twice 
as much as another gene), meant it was a technology that could stand competition already from 
the start, and produce new insights. 
 
DNA sequencing machines 
The last few years the rapid decrease in sequencing costs have markedly slowed down17, and 
Illumina's technology has taken most of the market18,19. I have seen the suggestion that Illumina 
is like Intel in the microprocessor business, only releasing improvements often enough to stay 
better than their competitors20. In 2008/2009, the SOLiD sequencing system was a close 
competitor, with a slightly lower price per sequence read but with lower quality and more 
difficult data analysis (Illumina was slightly better when we did the comparison in spring 2009, 
due to the large fraction of unmapped reads in SOLiD data). Since then, SOLiD has fallen 
behind21. Nowadays, Ion Torrent's technology is the main competitor to Illumina, and seems 
pretty close at least for machines (Ion Torrent PGM, Illumina MiSeq) that have lower throughput 
and high cost per read but higher speed and lower purchase cost22,23. 
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The latest development is the Illumina HiSeq X 10, for which Illumina calculates a cost per 
whole human genome sequence at just below US$1000, at the standard 30x coverage24. This 
particular price per human genome has for long been a goal25,26. There was even a prize, later 
canceled, for the first to reach this cost per human genome, called the Archon X prize27. Because 
of the high initial purchase cost and throughput, the HiSeq X 10 is suited only for large genomics 
centres28. Excluding the HiSeq X 10, the current sequencing cost for a human genome is around 
US$500029. 
RNA-sequencing 
RNA-seq analysis starts with RNA extraction from the biological sample. For single-cell 
protocols, this is merely a matter of placing the cell in a lysis solution, whereas for many bulk 
samples, the cells are dissociated from each other and there is an extra RNA purification step. 
The next step is library preparation, where the RNA is reverse transcribed into cDNA, which is 
then fragmented and universal adapter sequences, and DNA barcodes, are added to the ends of 
each fragment. The fragmentation step uses a separate kit (Nextera transposase) or machine 
(Covaris sonication) from the rest of the library preparation steps, and causes the fragment ends 
that will be sequenced to be distributed across the length of the gene and is needed to make the 
molecules short enough to work with common DNA sequencing machines (e.g. by Illumina or 
Ion Torrent30). 
Finally the cDNA library is sequenced, producing millions of so-called reads. A read is a partial 
(often 50bp) sequence of a cDNA fragment. Because DNA sequencing machines are expensive 
and thus should be constantly in use, the sequencing step is often done by a core facility or other 
service provider. One lane gives more than enough reads for an RNA-seq experiment, so several 
samples (often over ten in a lane) are generally sequenced together. They then need to be 
separated after sequencing (demultiplexing), using the DNA barcodes that were added during 
library preparation31. 
After the demultiplexing step, the sequences are aligned to the genome. The genome sequence 
contains introns whereas the reads mostly originate from spliced RNA. Therefore the alignment 
step needs to either include gene sequences with introns removed, or the alignment program has 
to be able to identify when reads cross from one exon to the next. Many such programs are freely 
and publicly available, e.g. TopHat32,33, RNA-STAR34 or GSNAP35. 
Quality control on sequenced samples can be done by a number of methods. The alignment 
success percent and absolute number of mapped reads I find are the best ways to spot trouble. 
Running the program FastQC36 can help discovering overrepresented sequence. Running NCBI 
Blast37 on a few reads (if a low fraction of the reads aligned to the genome of the species that 
should have been sequenced) to align against a broad variety of species can tell you if there is 
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contamination by DNA from a different organism. Because FASTQ files from Illumina's 
machines are sorted by location on the flow cell, it is a good idea to avoid the start and end of the 
file, where I have noticed that the error rate is higher38. If the reads align at a high frequency, it 
can next be a good idea to look at a few samples in a genome browser such as IGV39, to look for 
e.g. signs of DNA contamination (little mounds of alignment that do not follow genes and differ 
in location between samples) and alignment/assembly problems (such as regions with many 
mismatches next to each other). Finally, the fraction of reads aligning to exons, introns and 
intergenic regions tells you something about pre-mRNA fraction (gives more reads in introns), 
DNA contamination and alignment error (both these two increase the fraction of reads in 
intergenic regions). 
By counting the number of reads per gene, and knowing the gene length and the sequencing 
depth (the number of total reads for the library), the alignments can be summarised into one value 
per gene, using a metric called RPKM or FPKM (reads/fragments per kilobase and million 
mapped reads). I wrote my own program for RPKM calculation for Paper I, but several others are 
available. Cuffdiff40-42 appears to be the most popular one, and performs well for all but the 
shortest transcripts43. 
Some standard analysis methods to run are hierarchical clustering (I prefer Spearman correlation 
as metric and have seen the advice to use complete linkage), principal component analysis, and 
statistical testing for differential expression (DESeq44 is what I generally use, but several exist45). 
Hierarchical clustering provides additional quality control, as good samples all correlate well with 
one another since many genes are intrinsically highly or lowly expressed (e.g. ribosomal proteins 
that are highly expressed in all cell types). Bad samples show up as outliers in the hierarchical 
clustering. 
 
Figure 1. Illustration of hierarchical clustering, which can tell apart low quality samples (red) from better 
quality samples (green). The RF samples are from fibroblast cell culture, the rest are laser capture 
microdissected brain samples. 
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Principal component analysis allows you not only to find clusters of samples, but it also gives you 
a list of genes, weighted by importance (the U matrix of singular value decomposition46, if that is 
the method used), that drive the separation in a particular principal component. It also informs 
which separations are the strongest ones and which are the less informative ones, as each 
principal component contains a particular percent of the total variance. And it can show if some 
of the differences between groups are linearly dependent (they then line up one the same principal 
component). The main downside is the lack of P-values, making it hard to select clusters or know 
where to cut off the gene list coming from a principal component. If the first principal component 
separates the two groups you are interested in comparing, then a differential expression test 
solves that. It either gives a P-value for each gene, typically adjusted for multiple testing (the 
Benjamini-Hochberg FDR method47 is the most common) or it will tell you there are no 
significant differences, in the case when the clusters were not actually separate clusters. 
To identify functional groups among the differentially expressed gene, they typically go into a 
gene ontology analysis tool, such as DAVID48 or ToppFun49. It is also possible to use the genes 
with the highest or lowest weights in a principal component, or from fold change rankings, but it 
is not the standard way. Gene ontology analysis compares the input list of genes against a large 
number of pre-made gene lists (e.g. a biological function such as transcription, a location such as 
the mitochondrion or a pathway such as Wnt signaling) and tests for significant overlap between 
gene lists. 
Finally, most projects benefit from data analysis designed for just that one study. Here, 
programming is important, resulting in a bioinformatician writing a large number of small, single-
purpose programs, in languages such as R, python or perl50. And this is where most time is spent. 
 
ChIP-sequencing 
ChIP-seq is a DNA sequencing-based method to list genomic binding sites for a DNA-binding 
protein, by chromatin immunoprecipitation (ChIP). The first step is the application of 
formaldehyde to covalently bind proteins to adjacent DNA (fixation). The cells are then lysed to 
release their DNA, which is then fragmented by sonication to ~200-400 bp51. Some of this DNA 
is set aside as a negative control, with the fixation reversed. The rest is run through antibody 
capture for the protein of interest, with non-captured DNA washed away. Thereby DNA bound 
by that DNA-binding protein will be overrepresented in the sample. The formaldehyde crosslink 
is reversed and the sample becomes a sequencing library by adding universal adapters to the ends. 
Then one end of each DNA fragment (but not the adapters themselves) is sequenced.  
Alignments for ChIP-seq use simpler alignment programs than RNA-seq, since there is no intron 
splicing to account for. Bowtie52,53 has long been the most common program choice54, bwa55,56 is 
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also popular. The steps after alignment are peak call and peak annotation. Peak calling algorithm 
search for “peaks”, hill-like regions of read density about the same width as the DNA fragment 
length (a few hundred base pairs). During peak annotations, those peaks are associated with 
genes. Generally the closest gene within a set maximum distance is chosen. 
A new development for ChIP-seq analysis is the statistical concept irreproducible discovery rate, 
which uses replicates57. This is in contrast to the false discovery rate, which gets a distribution 
from a negative sample58 or in some cases a simulated random read distribution59. 
 
RNA-seq and ChIP-seq compared to qPCR alternatives 
Microarrays are still used60,61. But the main competitor to sequencing-based measurements is 
quantitative PCR, in the forms of qRT-PCR which quantifies RNA for a single gene, and ChIP-
qPCR which quantifies binding of a protein to a specific DNA stretch. In the early days, ChIP-seq 
and RNA-seq were often validated using ChIP-qPCR and qRT-PCR, respectively. Thankfully 
this habit seems to be disappearing. The problem is that qRT-PCR only provides technical 
validation (and only for the sequencing step), typically giving a strong correlation with fold 
changes from RNA-seq yet without validating biological findings62 unless it is performed across 
a larger panel of biological samples. 
For single-cell measurements, RNA-seq and qRT-PCR been reported to be equally good63. For 
measuring something lowly expressed in a bulk of much more highly expressed genes, I would 
trust qRT-PCR to have better sensitivity than RNA-seq, as highly expressed genes eat up the 
number of fragments that are sequenced in a sequencing run, leaving little sequencing depth for 
genes that are more lowly expressed by orders of magnitude. This is not a problem for single-cell 
RNA-seq, or even most tissue RNA-seq, as the dynamic range of expression levels is only so 
large (3 to 4 orders of magnitude16) but would make it hard to sequence from e.g. a few bacteria 
hidden in a tissue64. 
In a comparison between ChIP-seq and ChIP-qPCR, ChIP-seq has advantages even for single 
sites. Its genome-wide nature provides it with negative controls in the same experiment, making it 
much more reliable for finding a lack of binding. Also, ChIP-qPCR has to throw out negative 
results because they are inconclusive, which I suspect causes a bias (at weakly binding sites) that 
ChIP-seq would not have. But ChIP-seq suffers from being slow (sequencing queue time) and 
more expensive. For the purpose they are used – genome-wide discovery for ChIP-seq, single-site 
testing for ChIP-qPCR – ChIP-seq is said to require better antibodies to get sufficient sensitivity 
in comparison with ChIP-qPCR. 
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A sufficient sequencing depth 
There has been a tradition for RNA-sequencing to focus on the amount of sequence reads per 
sample, placing less emphasis on the number of replicates. Early studies did not always use 
replicates65, and currently, Encode recommends 30 million reads per RNA-seq sample as a 
minimum (corresponding to 20-25M mapped reads), but only 2 replicates. Lately the importance 
of replicates has been emphasized over the sequencing depth for individual samples66. My own 
opinion is based on analyses in papers I and III, where I found that detection (in bulk RNA-seq) 
and accuracy (in single-cell RNA-seq) of gene expression values from RNA-seq saturates after a 
few million reads. Thus I believe most studies will not require tens of millions of reads per 
sample, but should instead focus on increasing the number of replicates. 
 
Single-cell RNA-seq protocols 
Currently there are two kits available by different manufacturers (Clontech Smart-seq and Sigma-
Aldrich TransPlex). One of them, Smart-seq, has a single cell isolation machine built for it, the 
Fluidigm C1. There are also several published protocols: Quartz-seq
67, Tang et al. 201068, 
STRT69, Smart-seq270, CEL-seq71 and MARS-seq72. The C1 + Smart-seq system appears to be 
the most commonly used one. 
Single-cell RNA-seq protocols can use even small amounts of total input RNA, such as 10 pg. 
RNA-seq library preparation kits for bulk RNA (i.e. for a population of cells) have a much higher 
input requirement: 500 pg for Nugen Ovation v2, 50 ng for Agilent SureSelect, 100 ng for 
Illumina TruSeq. As a result, the single-cell RNA-seq protocols are being used not only for 
single-cell samples, but also for samples with, for example, ~100 cells, which is sufficiently many 
cells to average out cell-to-cell variation and give a low variation between replicate samples 
(Paper III, and seminar by Rahul Satija). The single-cell protocols lack the strand-specificity of 
some bulk RNA-seq protocols, but that is no great loss, while the gain is the ability to sort cells 
more carefully for the cell type you want to study, or to be able to use small biopsies. 
 
Improvement needs 
Early on (2008), issues for RNA-seq included a requirement for large amounts of RNA per 
sample (as much as for microarrays), lack of strand-specificity and to some extent a 3’ bias. The 
last two were soon solved for bulk RNA-seq, and single-cell RNA-seq has now solved the first 
one. Early on there were also little published in the way of algorithms and programs for RNA-
seq, e.g. there was no purpose-built alignment program for RNA-seq before TopHat32 in March 
2009. 
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Still today, the RNA sequencing protocols have room for improvement. Reducing the RNA loss – 
by reducing technical losses and by making them more foolproof against RNA degradation – 
would make the data easier to interpret and reduce sample variability that obscures biological 
differences. Adding multiplexing (preparing many samples together), which is done by tagging 
cDNA fragments with DNA barcodes, could help somewhat to increase the number of samples, 
but would soon run into the DNA sequencing machine's limit on throughput, which at the 
moment is increasing rather slowly17. 
On the bioinformatics side, alignment is today the most mature, suffering only from high RAM 
usage (but with the continuous computer hardware improvements, even laptops will have 
enough). Aligning two samples for the same tissue to the genome but with different alignment 
programs (TopHat32, RNA-STAR34 and GSNAP35 are the ones I have tested) gives you strikingly 
similar results. Quality control and clustering can both be done without much difficulty with 
current methods. Statistical methods for determining the most significant gene expression 
differences between two sample groups is the least developed part, and better algorithms are 
needed. This is especially the case for single-cell data, which is rich in zeros (as expression 
measurements) both due to biological stochasticity and technical losses. One problem I have 
encountered is that assigning samples to groups randomly can sometime give significant genes, 
perhaps due to an outlier value in one sample for a gene that gets called significant. Other issues 
are biases based on gene expression level as well as big differences between algorithms' outputs. 
More options for paired experimental setups would also be helpful. But it is hard to say how 
much of a problem these issues represent, before there RNA-seq studies are attempted to be 
replicated (in the sense of same question and choice of sample types, but new samples and people 
analysing them). Microarrays have a history of producing gene sets that differ too much between 
studies73, so RNA-seq studies that produce differential expression gene might suffer from a 
similar problem until the statistical understanding improves. 
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AIMS 
• To determine general features about gene activity in cells, such as “How many genes are 
needed for housekeeping functions, how many do specialised functions in a cell type?” 
• To improve computational analysis of RNA-seq data, e.g. defining detection limits and 
required sequencing depth 
• To understand how gene regulation over developmental time is achieved by transcription 
factors with similar DNA binding properties. 
• To evaluate single-cell RNA-seq, including its accuracy, sensitivity and gene body 
coverage. 
• To clarify aspects of pre-implantation development, in particular the replacement of 
maternal RNA by embryonic transcription 
• To characterise allelic expression patterns in individual cells 
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RESULTS AND DISCUSSION 
 
An abundance of ubiquitously expressed genes 
Findings in Paper I: 
• Tissues usually express 11,000-13,000 protein-coding genes 
• Most of these expressed genes can be found expressed in any tissue 
• RNA-seq has background, at below 0.3 RPKM 
• A few million reads are enough to saturate gene detection 
• The liver transcriptome is dominated by a few genes, unlike most tissues 
Before RNA-seq, the main methods to measure the activity of genes were qPCR and microarrays. 
Neither qPCR nor microarrays measure absolute expression values, unless a standard curve for 
each gene is prepared. RNA-seq differs in this aspect: it can, fairly well, tell that e.g. RNA from 
gene A is twice as abundant as RNA from gene B. Thus the arrival of RNA-seq provided an 
opportunity to study the ”shape” of the transcriptome. RNA-seq also has the advantage of being 
able to tell which nucleotides of a gene are expressed, whereas previous methods generally 
interrogated a pre-selected part of the gene being measured. This allows RNA-seq to tell which 
parts of the gene structure are being expressed. Nowadays it can also discover genes without help 
of prior annotation74, but in 2008 and 2009, the read lengths were shorter and there were fewer 
assembly programs (and none designed for RNA)75, which are the programs needed to put 
together reads outside known genes into new gene structures and tell these reads apart from 
various types of background. 
Paper I deals with questions about the structure of the transcriptome (all the expressed RNA): 
How many genes are active in a tissue? Which genes are always needed? Why are some 
messenger RNAs short and others long? In addition it deals with technical questions, such as 
background level and required sequencing depth. 
I counted the number of expressed genes per tissue in Paper I. Microarrays, the only previous 
genome-wide method, do not have as good sensitivity as RNA-seq. The 200 intensity threshold 
for detection on Affymetrix arrays corresponds to 3-5 RNA copies per cell76,77 whereas RNA-
seq, as it turned out, could detect expression at 0.1 copies per cell (I calculated in the paper that 
0.3 RPKM was an appropriate threshold, Mortazavi et al 200816 had found that 3 RPKM in a 
liver cell, with nearly the same protocol, corresponded to 1 copy per cell). I found that 11,000-
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13,000 different (protein-coding) genes were expressed for most of the tissue samples (8,000 of 
those genes were detected in all the tissues I had RNA-seq data for). Though ~12,000 is not that 
far from what the most thorough microarray study78 had found, which was 8,200 on average. I 
am pleased to see that the numbers I calculated have been used for validation of transcriptome 
assemblies79-81. The list of ubiquitously expressed genes has also proven useful for focusing on 
tissue-specific genes when testing for differential expression82. 
Paper I also analysed the length of the untranslated regions of mRNAs. Among the tissues, brain 
had by far the longest untranslated regions. The paper only shows the result for mouse, but it was 
the same in human. I never included the human samples because these had a problem with RNA 
degradation, which shortens the mRNAs and which I indirectly measured using the read density 
ratio between the 3' and the 5' ends of the coding regions of all genes. Tellingly, breast and fat 
tissue were the samples unaffected by RNA degradation. 
There are studies from the 1970s that found a multi-modal distribution of gene expression 
values83-86, with two or three quite small groups of highly expressed genes giving distinct peaks 
in the gene expression distribution. I mentioned in Paper I that these groups were not present in 
the RNA-seq data, but it was all a mono-modal distribution. Those groups of highly expressed 
genes have never been found again (they were probably created by bad maths). However, a study 
published in 201187 argues that the bump in the low end of the distribution, which I had 
dismissed as non-expressed background from alignment or DNA contamination, were actually 
transcribed genes, though non-functional. That would be a reason for a biological, rather than 
technical, gene expression cut-off, located at somewhere 1-5 RPKM. However, I have seen the 
bimodal distribution with a low-expression group under 1 transcript per cell (first commented on 
in a email by Quin Wills) even for single-cell RNA-sequencing data (of papers III and IV), and 
heard from others (Sten Linnarsson) about a similar bump in their expression level distributions, 
so it does seems to be a technical issue. 
The most common question I get on this paper has been how to calculate a threshold RPKM level 
by the method in Paper I. It seems that providing the algorithm as text and formulas only got 
people partway to being able to implementing it (though some papers seem to have 
reimplemented the algorithm without further help than the paper). Sending them code did work. 
But it means fewer will have tried the algorithm then would have otherwise tried. Hopefully the 
less short-handed descriptions in Papers II-IV (their methods sections can be as long as the rest of 
the paper combined) reduces this issue of difficulty of reuse that Paper I had.  
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Sequentially acting Sox transcription factors 
Findings in Paper II: 
• Sox2, Sox3 and Sox11 bind to mostly to the same enhancers 
• Sox proteins can bind enhancers long before the enhancer becomes active 
• Sox3 can induce histone modifications (histone 3 lysine 4 and 27 trimethylation) 
The Sox gene family of transcription factors has expanded during vertebrate evolution, to 20 
genes in human and mouse, which can be categorized into 9 groups, e.g. the SoxB1 group is 
Sox1, Sox2 and Sox388. The first reported Sox gene, Sry, was identified by its role in sex-
determination. The rest of the family was than classified as Sox proteins by containing the same, 
well-conserved DNA-binding domain as Sry. Other than the DNA-binding domain, the groups 
are not similar and appear to have domains that function differently outside the DNA-binding 
domain. 
Plenty of the Sox proteins are involved in brain development. The weakly activating SoxB1 are 
active early in development, and function to maintain neural stem and progenitor cells, which are 
the self-renewing cell types of the brain and spinal cord. SoxB2 proteins (Sox14, Sox21) are also 
present in these cells, but are repressive transcription factors, counteracting the role of the SoxB1 
genes. As cells differentiate, SoxC (Sox4, Sox11, Sox12) proteins become active in 
differentiating neurons, and SoxE (Sox8, Sox9, Sox10) proteins are important in the astrocytes 
and oligodendrocyte lineages, which have supporting roles in the brain. 
Paper II investigated how Sox proteins perform their role during brain and spinal cord 
development, by looking at the sites in the mouse genome where Sox2, Sox3 and Sox11 bind in 
the relevant cell types, which were neural progenitor cells for Sox2 and Sox3, and early neurons 
for Sox11. There was already a published dataset for Sox2 in mouse embryonic stem cells, which 
I included in the analysis. 
Excluding the embryonic stem cell dataset, the binding of Sox2, Sox3 and Sox11 overlapped very 
well, with essentially no independent binding sites for Sox2 and Sox11, and overlap at 70% of the 
Sox3 sites (pretty much the same Sox3 sites had Sox2 and Sox11 binding, so there is a 30% 
subset of Sox3-specific sites, though that could be the higher quality of the Sox3 dataset). The 
high overlap with Sox11 was not an expected result. The cell type was not the same, and Sox11 
has a rather different function, driving differentiation instead of inhibiting differentiation as the 
SoxB1 genes do when over-expressed. But it did fit with ideas about Sox proteins as transcription 
factors that bind early to keep a place on the DNA available for later binding by another 
transcription factor, such as another Sox protein, in a later cell type. For example, Sox2 binding in 
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embryonic stem cells, at one enhancer, had been shown to allow later Foxd3 binding89, and some 
Fox transcription factors have been shown to keep chromatin open for other Fox proteins90. 
Paper II contains both microarray, RNA-seq and ChIP-seq data, but not the array equivalent of 
ChIP-seq, which is chip-on-chip. The project started with its own microarray data, and later 
added microarray data from gene expression omnibus, a database of published microarrays. 
However, due to quality concerns, we later added RNA-seq expression datasets of our own. The 
reason was quality. Microarrays get signals from genes mixed together and have a low dynamic 
range, producing problems for highly and lowly expressed genes. And RNA-seq was not much 
more expensive at the time (the difference has since been reduced further). For the choice 
between ChIP-seq and chip-on-chip, the advantages of the sequencing technique are much 
greater91. In 2008 chip-on-chip was already a technique on the way out, as it either gives up the 
discovery potential, by limiting probes to a set of sites, or is very expensive, if the entire genome 
is covered, and still has worse sensitivity and resolution. 
Midway through the course of the project, I heard the results of a study92 that compared the DNA 
binding of two proteins (CEBPA and HNF4A) in five different species, which concluded that 
very few of the binding sites are conserved during evolution. Only 7-14% of binding sites were 
the same between human and mouse, and nothing says Sox proteins would have more conserved 
binding. Their finding was backed up by a previous paper of theirs93 which performed ChIP-seq 
(for 3 evolutionary unrelated transcription factors: HNF1A, HNF4A, HNF6) in a mouse with an 
added human chromosome 21. This study93 found that the human chromosome bound the 
transcription factors as they do in people, whereas the homologous mouse regions (which consist 
mainly of chromosome 16) bound them differently. 
This means the sites we find may not be that useful for human studies, as they will not be at the 
homologous locations. Yet the principles for how Sox genes function, should nonetheless hold 
true in other species such as mouse, and can probably be generalized to other transcription factor 
families. 
Some ChIP-seq samples were lower-quality, and gave a thousand or so peaks by de novo peak 
calling. They were still helpful, because I could test binding sites known from better-quality 
ChIP-seqs, tens of thousands of them, on the data from the worse-quality ChIP-seq. To do so, I 
adopted the signal/background comparison method of paper I, using either peak-sized regions 
near the peaks, or read counts from the input as the negative set. Though with a low sequencing 
depth (only millions of reads) it could be hard to be sure that regions that seem negative really are 
that. 
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mRNA-seq from single cell levels of RNA 
Findings in Paper III: 
• This is a new RNA-seq library preparation method that works even for RNA from only 
one cell 
• With medium amounts of input RNA (1 ng) this method works as good as bulk RNA-seq 
• Reads from this method are distributed across the length of each gene 
• Isolation by the marker NG2 can find cells in the blood migrating from a melanoma 
While my two first papers are based on samples with at least hundreds of thousands of cells, the 
aim was to do a study on pre-implantation development (which is the first week of pregnancy in 
human), where the number of cells is rather more limited, between one and about a hundred cells 
per embryo. So I would need single-cell RNA-sequencing, and therefore my PhD project plan 
included that I take part in single-cell RNA-sequencing methods development. 
The first single-cell RNA-seq dataset came in April 200994, using a method that was a slightly 
modified version of a single-cell microarray protocol95. The cell was an oocyte, which is much 
larger than normal cells (~50 times) but still its ~1 ng of total RNA is much less than the 
recommended minimum of 100 ng in Illumina's standard RNA-seq protocol called TruSeq 
(though people seem to get those to work with just tens of nanograms). Rickard Sandberg (my 
PhD supervisor) had a single-cell RNA-sequencing project on pre-implantation mouse embryos 
in mind since he started in 2008, so this was exciting. I evaluated the oocyte data to see if the 
protocol had worked well, and concluded that it did. One thing deviated from the description in 
the paper94: it rarely produced full-length cDNA, but mostly <500 bp, and sometimes when it 
seemed to have done so, it was actually priming on poly(A) stretches within the RNA. It was 
nonetheless exiting news that an apparently working single-cell RNA-seq protocol was around. 
Both I and a master thesis student in our group, Sigrid Karstorp, tried the protocol95 but it would 
not work; neither of us got amplified cDNA out of it. Meanwhile, I tried to get my re-analysis of 
the Tang et al. 200994 data published, but failed (rejected by two journals, then we gave up). It 
later formed the nucleus of Paper III. 
A year later, near the end of 2010, Rickard Sandberg showed my single-cell RNA-seq data re-
analysis to Gary Schroth at the company Illumina. As a result, our lab was invited to beta test a 
new protocol for single-cell RNA-seq that Illumina was developing, and we were sent data from 
test runs of their protocol, which I could quickly analyse because I already had the tools 
developed. In the end we set up collaboration, where Illumina supplied their test data, and we 
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were allowed to analyse it essentially without interference from them and with the option to 
publish what we found.  
 
Figure 2. This single figure was prepared but never published for my re-analysis of the Tang et al. 2009 
single-cell RNA-seq data. (A) Read density across the length of genes. The first plot represent genes 0-1,000 
bp long, the second 1,000-2,000 bp etc. (B) 3’ bias as a function of poly(A) sequences in the gene. (C) 
Spearman correlation between the gene length and expression for all genes expressed >1 RPKM. (D) The 
contribution of the most expressed genes to the total number of mRNA molecules, where the x axis show the 
cumulative number of genes sorted by expression. (E) Gene expression in genes and background regions in 
the blastomere sample. (F) Venn diagram showing the number of genes detected (>0.2 RPKM) in oocytes, 
and the concurrence of replicates. (G) The agreement (“detection in both”) between single-cell or tissue 
replicates, at fixed sequence depth. (H) The fraction of genes detected in two samples as a function of gene 
expression level. (I) Variation in expression level estimates using between two samples as a function of gene 
expression. 
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Paper III presents a new method for RNA-sequencing from small amounts of RNA, down to 
RNA from single cells, and data analysis of how well the method works. For example we 
compared how high the technical noise level was at different gene-expression levels in 
comparison to biological differences, and we looked at how far along the length of the RNA there 
was cDNA formed that was then sequenced. To show that the method works on a 
biologically/medically relevant sample, we included an analysis of melanoma cells which had 
migrated into the bloodstream of a person with cancer, and I generated a list of genes for surface 
antigens that were specific to some degree to theses melanoma cells. 
Manufacturer's descriptions of their protocols can be understated, presumably not wanting to 
disappoint customers who would try the protocol at the limit of its ability, at least RNA input 
amounts are conservative. Scientists on the other hand can be a bit too optimistic about method 
performance, or maybe that is a result of pressure from journal editors. We are aware that the 
description “full-length” was a bit of an overstatement and it would have been more accurate to 
call it “nearly full-length”, since the reverse transcriptase does not perfectly extend to full-length 
cDNA, missing the end for 60% of the time. The title and the associated news&views article96 
proclaims “full-length” as the main thing, pushed by our expectations of journal opinion and by 
one reviewer, even though our own conclusion was rather that, based on that the data quality and 
the kits that worked for Qiaolin Deng in our group right off, it was the first single-cell RNA-seq 
protocol which was worth using. 
The main factor for sample quality of single-cell cDNA libraries is how much of the starting 
RNA contributes to the sequenced cDNA, i.e. yield. Paper III did not include the spike-in RNA 
controls (bacterial RNA added in known amounts to the sample before reverse transcription and 
amplification) needed to calculate the yield. One recent paper97 calculated 10% as its Smart-seq 
yield per starting RNA, although with quite a bit of variation between individual RNA spikes. 
Based on the two least abundant spikes in Paper IV, I calculated a ~15% yield, which is in good 
agreement. It is a fairly low number, and as a result, both lowly and medium (<100 RPKM) 
expressed genes suffered from lots of technical variation. A few people in our group, Simone 
Picelli in particular, tried to further develop the Smart-seq protocol70,98 and got the yield up, to 
40% (see calculation in Paper IV figure S26 and the data in its figure 3A). 
One type of graphical tool that I developed turned out to be especially useful, for Paper III and for 
other RNA-seq protocol development projects (including Picelli et al. 201398 in the group. It bins 
genes by RPKM expression number, and shows a “detection” percent for each expression bin of 
genes. It is calculated on a pair of samples, as the fraction of genes detected in either sample that 
are detected in both. If there are more than two, they are matched into pairs and the average is 
shown Because the technical dropout of genes is a function of cDNA molecule number, and 
RPKM implicitly includes a normalisation for the total amount of cDNA, the line in the plot 
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shifts to the right (more cDNA) or left (less cDNA) depending on how many molecules there are 
reads from, which is a function of yield and input RNA amount. 
The Smart-seq protocol/kit (SMARTer Ultra Low Input RNA Kit for Illumina Sequencing) is, as 
far as my February 2014 literature search can tell, the most popular single-cell RNA-seq protocol. 
I can spot 9 papers, excluding technical comparisons and evaluations, that use it. It help that this 
kit was well tested before release, as evidenced by sending it out for beta testing. Another factor 
is the Fluidigm C1 machine. The C1 is a microfluidics system that takes a single cell suspension, 
gets cells into separate wells (96 wells per run) and performs Smart-seq library preparation within 
the machine, i.e. it automates the Smart-seq procedure. 
 
Dynamic, random monoallelic gene expression 
Findings in Paper IV: 
• Randomness in transcription causes 12-24% of the genes to only be represented in the 
transcriptome by one of two gene copies 
• The two copies of a gene are independently transcribed from one another 
• The paternal X chromosome is initially activated in 2-cell stage embryos, but soon gets 
inactivated 
• By the four-cell embryonic stage, there is little remaining maternal RNA 
To some extent, Paper IV is about embryonic development during the first few days, where our 
plan was to learn more about the degradation of RNA that is left from the oocyte and by what 
time cells begin to become different cell types. But in particular, this paper deals with an 
unexpected phenomenon we observed, that in the individual cell there will not always be RNA 
from both copies of each gene, but sometimes only from one, in a way that is random, rapidly 
changing and affecting virtually all expressed genes. There are several mechanisms that can 
underlie this observation. One is transcriptional bursting, i.e. that genes are transcribed into 
several RNA at a time and then is silent for a long time99. Another mechanism is inherited 
random monoallelic expression, where a randomly chosen copy of a gene is the only one 
expressed over many cell divisions, as many as 15 divisions100. This type of monoallelic 
expression was recently shown to be rarer in embryonic stem cells than elsewhere101, perhaps 
because whatever the changes to chromatin and transcription factor binding that causes it, those 
are changing at a faster pace in embryonic stem cells and its related cell types during pre-
implantation development. I did see a few percent of the monoallelicly expressed genes (over 
expected) with a coordinated, same allelic choice as their neighbour genes (Paper IV figure S4E), 
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which suggests that some of the monoallelic expression was driven by the same thing as whatever 
causes inherited monoallelic expression. But mostly what I observed must be a consequence of 
transcriptional bursting, and this implies that the burst frequencies are low compared to RNA 
degradation rates, causing both monoallelic expression and, for something like 1% of the genes 
(based on 20% monoallelic expression: (1-0.1)⋅(1-0.1)-0.1⋅0.1=0.2, 0.1⋅0.1=0.01) that “should” 
be expressed, loss of all gene expression. But there is also a third suggested mechanism102: that 
replication-induced supercoiling at the promoter can randomly hinder or aid transcription of each 
allele. 
Half or more of the genes appeared to have monoallelic expression in each of our Smart-seq 
single-cell samples. But from a simulation of molecule loss (Paper IV figure S4D) I could see that 
while some of the monoallelic expression must be real, a great part was a technical artifact. A key 
experiment (demanded by a reviewer and soon thereafter published in a slightly different, ten cell 
version97) was to split the contents of a lysed cell into two tubes and prepare and sequence two 
separate samples. While the ten cell version of it was inconclusive97, with the single split cell 
version I could make an algorithm (Paper IV figure S26) that looks at how often the two samples 
say the same thing and from that calculate loss frequency and what the monoallelic fraction of 
gene expression was before those losses. 
The implications of random monoallelic expression lie in the understanding of the effects of 
heterozygous mutations and SNPs. The same heterozygous genotype at a locus can have effects 
that vary much between individuals (variable expressivity) or randomly gives one of two 
phenotypes (penetrance). Perhaps it is because development takes a slightly different path 
depending on which allele of a gene is expressed in a critical cell and developmental time point. 
One of the greatest challenges turned out to be to get a good list of genetic differences between 
the two mouse strains we were using. The genomes for both strains had been sequenced (one of 
them, for C57BL/6, is the mouse reference genome), and there was a database where I could get a 
list of genetic differences between two chosen strains. But the SNPs (single base pair differences, 
pronounced snips) need to be trustworthy. If I list a position as A in the strain C57BL/6 and G in 
the strain CAST/Ei, but that position is A in both, then I will get false detection of the C57BL/6 
allele when the CAST/Ei allele at that position is expressed. This type of error turned out to be 
very common in the database, presumably due to sequencing errors in the CAST/Ei genome that 
were interpreted as SNPs. As a result, the initial read assignment to alleles got it wrong about half 
the time (some of my samples were from a single strain background, these acted as controls and 
gave error rates).  I first derived my own set from the pure CAST/Ei samples and the reference 
genome, but eventually we used the database SNPs but filtered them for SNPs that were 
“heterozygous” in the sum of our samples. A sign that it worked is the similar number of genes 
with only CAST/Ei or only C57BL/6 allele expression (errors would give a C57BL/6 bias), 
visible in the figures in Paper IV that show maternal and paternal monoallelic as separate bars. 
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The paper ended up with much less focus on embryonic development than originally planned. I 
did determine e.g. where the cells started to become different from the other cells in the same 
embryo (between 8-cell and 16-cell stage), but that time point was not a great surprise103. The 
data is publicly available though104 for anyone who wants to know which genes are expressed 
when during mouse pre-implantation development. 
 
Future perspectives 
The transcriptional dynamics is something you need to have an idea about to make use of single-
cell transcriptome data, for example to differentiate between on-off changes and changes from 
one expression level to the other, or to understand what level of variation is technical, biological 
within a cell type, or indicative of several cell types. But it is as a tool for a wide range of 
exploratory biological studies I see the use of this kind of measurements in the near future. 
Methods that use measure on the RNA from a large number of cells miss some features of the 
sample: the on-off dynamics of genes105, and cell type composition. They are also cumbersome to 
use on specific cell types, requiring cell culture and limiting to what extent cells can be selected 
for a particular sub-population. 
Single-cell RNA-seq will be useful particularly for cell type discovery. One strategy would be to 
dissociate a tissue into cells and perform single-cell RNA-seq on many of them, and then find 
clusters among their gene expression profiles105. Another strategy would be to narrow down cell 
types using other gene expression profiling methods that can only measure a small number of 
genes at a times, and then use single-cell RNA-seq to verify that the cell-type is homogeneous 
and different from other cell types that are sampled at the same time, or equally important to find 
that this is not the case and that the presumed cell type may have subtypes or unexpected 
similarity to another cell type. 
For medical diagnostics, the use of RNA-sequencing is still far off – microarrays are so far only 
used for one test (MammaPrint)106, so there is a considerable lag compared to biological research. 
However, hospitals are likely to procure DNA sequencing machines (the kind with moderate 
throughput but fast speed, like the Illumina MiSeq) in the near future, for testing for mutations 
and aneuploidy. Thus RNA-seq does not suffer from the same equipment problem that makes 
microarrays slow, this should help. 
In vitro fertilisation is a field that is unusually open to innovation and trying out new techniques. 
Because RNA is an amplification step away from DNA, and much of it is conveniently tagged 
with a common sequence at one end (the poly(A) tail) that makes primer binding easy, RNA 
sequencing has some advantages over the more direct DNA sequencing for mutations. And it 
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measures the outcome of gene regulation, in a way that looking and the regulatory DNA elements 
will not help with (the knowledge about them is way too small). 
Cheers for reading this far! 
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